Over the past decade, researchers have made great strides in the development and administration of cancer immunotherapies, which use the body's own immune system to treat disease. However, the therapies don't work for every ...
May 25, 2022
0
119
Access to therapies approved over the last decade has significantly lengthened median survival times in patients with metastatic hormone-sensitive prostate cancer. That conclusion comes from a large randomized clinical trial ...
May 2, 2022
0
14
Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate ...
Apr 22, 2022
0
19
Fighting cancer and chronic disease is tiring work for the immune system. When T cells are engaged in this kind of lengthy battle, they can become exhausted, or unable to function properly. One immunotherapy that revitalizes ...
Apr 18, 2022
0
74
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cells are more precise and sophisticated in their ability ...
Apr 15, 2022
0
27
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses ...
Apr 14, 2022
0
16
Many men stopped getting screened for prostate cancer after a federal advisory committee said in 2008 that the tests weren't helpful for those over 74. Then in 2012, it said the evidence supporting tests for younger men was ...
Mar 21, 2022
0
3
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, ...
Mar 21, 2022
0
44
The first FDA-approved gene therapies are living drugs: immune cells taken from cancer patients engineered to target tumor cells. However, for many patients, these advanced therapies do not result in a long-lasting remission. ...
Mar 16, 2022
0
95
A novel prostate cancer treatment—225Ac-PSMA-617 radioligand therapy—has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) ...
Mar 9, 2022
0
3
